PMID- 31665912
OWN - NLM
STAT- MEDLINE
DCOM- 20200910
LR  - 20231112
IS  - 1555-3892 (Electronic)
IS  - 0963-6897 (Print)
IS  - 0963-6897 (Linking)
VI  - 28
IP  - 12
DP  - 2019 Dec
TI  - Combination treatment of autologous bone marrow stem cell transplantation and 
      hyperbaric oxygen therapy for type 2 diabetes mellitus: A randomized controlled 
      trial.
PG  - 1632-1640
LID - 10.1177/0963689719883813 [doi]
AB  - The objective of this study was to compare standard treatment versus the 
      combination of intrapancreatic autologous stem cell (ASC) infusion and hyperbaric 
      oxygen treatment (HBOT) before and after ASC in the metabolic control of patients 
      with type 2 diabetes mellitus (T2DM). This study was a prospective, randomized 
      controlled trial. The combined intervention consisted of 10 sessions of HBOT 
      before the intrapancreatic infusion of ASC and 10 sessions afterwards. ASCs were 
      infused into the main arterial supply of the pancreas to maximize the presence of 
      the stem cells where the therapeutic effect is most desired. A total of 23 
      patients were included (control group = 10, intervention group = 13). Age, 
      gender, diabetes duration, number of medications taken, body weight and height, 
      and insulin requirements were recorded at baseline and every three months. Also, 
      body mass index, fasting plasma glucose, C-peptide, and HbA1c, C-peptide/glucose 
      ratio (CPGR) were measured every three months for one year. HbA1c was 
      significantly lower in the intervention group compared with control throughout 
      follow-up. Overall, 77% of patients in the intervention group and 30% of patients 
      in the control group demonstrated a decrease of HbA1c at 180 days (compared with 
      baseline) of at least 1 unit. Glucose levels were significantly lower in the 
      intervention group at all timepoints during follow-up. C-peptide levels were 
      significantly higher in the intervention group during follow-up and at one year: 
      1.9 +/- 1.0 ng/mL versus 0.7 +/- 0.4 ng/mL in intervention versus control groups, 
      respectively, p = 0.0021. CPGR was higher in the intervention group at all 
      controls during follow-up. The requirement for insulin was significantly lower in 
      the intervention group at 90, 180, 270, and 365 days. Combined therapy of 
      intrapancreatic ASC infusion and HBOT showed increased metabolic control and 
      reduced insulin requirements in patients with T2DM compared with standard 
      treatment.
FAU - Estrada, Esteban J
AU  - Estrada EJ
AD  - Hospital de Alta Complejidad Pte. Juan Domingo Peron, Formosa, Argentina.
FAU - Decima, Jose Luis
AU  - Decima JL
AD  - Hospital de Alta Complejidad Pte. Juan Domingo Peron, Formosa, Argentina.
FAU - Bortman, Guillermo
AU  - Bortman G
AD  - Hospital de Alta Complejidad Pte. Juan Domingo Peron, Formosa, Argentina.
FAU - Roberti, Javier
AU  - Roberti J
AUID- ORCID: 0000-0002-4285-5061
AD  - Hospital de Alta Complejidad Pte. Juan Domingo Peron, Formosa, Argentina.
FAU - Romero, Elida Beatriz
AU  - Romero EB
AD  - Hospital de Alta Complejidad Pte. Juan Domingo Peron, Formosa, Argentina.
FAU - Samaja, Gustavo
AU  - Samaja G
AD  - Hospital de Alta Complejidad Pte. Juan Domingo Peron, Formosa, Argentina.
FAU - Saavedra, Aldo Rodriguez
AU  - Saavedra AR
AD  - Hospital de Alta Complejidad Pte. Juan Domingo Peron, Formosa, Argentina.
FAU - Martinez, Gerardo
AU  - Martinez G
AD  - Hospital de Alta Complejidad Pte. Juan Domingo Peron, Formosa, Argentina.
FAU - Gutierrez, Samuel
AU  - Gutierrez S
AD  - Hospital de Alta Complejidad Pte. Juan Domingo Peron, Formosa, Argentina.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20191030
PL  - United States
TA  - Cell Transplant
JT  - Cell transplantation
JID - 9208854
SB  - IM
MH  - Aged
MH  - *Bone Marrow Transplantation
MH  - Diabetes Mellitus, Type 2/blood/*therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - *Hyperbaric Oxygenation
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Transplantation, Autologous
PMC - PMC6923554
OTO - NOTNLM
OT  - autologous transplantation
OT  - clinical trial
OT  - diabetes
OT  - stem cell therapy
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2019/11/02 06:00
MHDA- 2020/09/12 06:00
PMCR- 2019/12/01
CRDT- 2019/11/01 06:00
PHST- 2019/11/02 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
PHST- 2019/11/01 06:00 [entrez]
PHST- 2019/12/01 00:00 [pmc-release]
AID - 10.1177_0963689719883813 [pii]
AID - 10.1177/0963689719883813 [doi]
PST - ppublish
SO  - Cell Transplant. 2019 Dec;28(12):1632-1640. doi: 10.1177/0963689719883813. Epub 
      2019 Oct 30.